PPAR-γ Pro12Ala genotype and risk of cognitive decline in elders

被引:26
作者
Yaffe, K.
Kanaya, A. M.
Lindquist, K.
Hsueh, W. C.
Cummings, S. R.
Beamer, B.
Newman, A.
Rosano, C.
Li, R.
Harrisi, T.
机构
[1] Univ Calif San Francisco, Dept Psychiat & Neurol, San Francisco, CA 94121 USA
[2] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Geriatr, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[5] San Francisco VA Med Ctr, San Francisco, CA USA
[6] Calif Pacific Med Ctr, San Francisco, CA USA
[7] Johns Hopkins Univ, Dept Med, Baltimore, MD USA
[8] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA
[9] Univ Tennessee, Ctr Hlth Sci, Ctr Genom & Bioinformat, Dept Prevent Med, Memphis, TN 38163 USA
[10] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA
关键词
cognitive function; PPAR-gamma; cognitive impairment; dementia; metabolism;
D O I
10.1016/j.neurobiolaging.2006.09.010
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) has been associated with decreased risk of diabetes and obesity, both disorders linked to cognitive impairment. We tested whether this polymorphism is associated with cognition. Methods: Two thousand nine hundred sixty-one participants (mean age, 74.1; 41% Black; 52% women) were administered the Modified Mini-Mental State Examination (3MS) and Digit Symbol Substitution Test (DSST) at baseline and 4 year follow-up. Test scores were adjusted for age, sex, education, cerebrovascular disease, depression and APOE genotype and additionally for race. We determined the association between Ala allele and development of cognitive decline (3MS decline of >= 5 points). Results: At baseline, unadjusted scores on both cognitive tests were higher for Ala carriers compared to non-carriers (3MS, 94.2 versus 92.5, p<0.001; DSST, 40.2 versus 34.5, p<0.001). Similarly, follow-up scores were higher for Ala carriers. Multivariable adjustment led to similar results; additional adjustment for race attenuated the baseline 3MS results. After 4 years, 17.5% of Ala carriers developed cognitive decline compared to 25% among non-carriers (unadjusted OR = 0.61; 95%CI, 0.46-0.82; adjusted OR = 0.75; 95%CI, 0.55-1.02). Further adjustment for metabolic variables including fasting blood glucose and lipid level did not change the results. Conclusions: The PPAR-gamma Ala12 allele carriers may have less risk of developing cognitive decline. (C) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:78 / 83
页数:6
相关论文
共 29 条
[1]   The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes [J].
Altshuler, D ;
Hirschhorn, JN ;
Klannemark, M ;
Lindgren, CM ;
Vohl, MC ;
Nemesh, J ;
Lane, CR ;
Schaffner, SF ;
Bolk, S ;
Brewer, C ;
Tuomi, T ;
Gaudet, D ;
Hudson, TJ ;
Daly, M ;
Groop, L ;
Lander, ES .
NATURE GENETICS, 2000, 26 (01) :76-80
[2]   Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations [J].
Beamer, BA ;
Yen, CJ ;
Andersen, BE ;
Muller, D ;
Elahi, D ;
Cheskin, LJ ;
Andres, R ;
Roth, J ;
Shuldiner, AR .
DIABETES, 1998, 47 (11) :1806-1808
[3]   IMPROVED DIGIT SYMBOL SUBSTITUTION BY OLDER WOMEN AS A RESULT OF EXTENDED PRACTICE [J].
BERES, CA ;
BARON, A .
JOURNALS OF GERONTOLOGY, 1981, 36 (05) :591-597
[4]   Role of the peroxisome proliferator-activated receptor-γ (PPAR-γ) and its natural ligand 15-deoxy-Δ12,14-prostaglandin J2 in the regulation of microglial functions [J].
Bernardo, A ;
Levi, G ;
Minghetti, L .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 (07) :2215-2223
[5]   Risk of dementia in diabetes mellitus: a systematic review [J].
Biessels, GJ ;
Staekenborg, S ;
Brunner, E ;
Brayne, C ;
Scheltens, P .
LANCET NEUROLOGY, 2006, 5 (01) :64-74
[6]   The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes [J].
Clement, K ;
Hereberg, S ;
Passinge, B ;
Galan, P ;
Varroud-Vial, M ;
Shuldiner, AR ;
Beamer, BA ;
Charpentier, G ;
Guy-Grand, B ;
Froguel, P ;
Vaisse, C .
INTERNATIONAL JOURNAL OF OBESITY, 2000, 24 (03) :391-393
[7]   Inflammatory mechanisms in Alzheimer's disease:: Inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists [J].
Combs, CK ;
Johnson, DE ;
Karlo, JC ;
Cannady, SB ;
Landreth, GE .
JOURNAL OF NEUROSCIENCE, 2000, 20 (02) :558-567
[8]   Insulin and neurodegenerative disease: shared and specific mechanisms [J].
Craft, S ;
Watson, GS .
LANCET NEUROLOGY, 2004, 3 (03) :169-178
[9]   A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity [J].
Deeb, SS ;
Fajas, L ;
Nemoto, M ;
Pihlajamäki, J ;
Mykkänen, L ;
Kuusisto, J ;
Laakso, M ;
Fujimoto, W ;
Auwerx, J .
NATURE GENETICS, 1998, 20 (03) :284-287
[10]   Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-γ2 (PPAR-γ2):: divergent modulating effects on body mass index in obese and lean Caucasian men [J].
Ek, J ;
Urhammer, SA ;
Sorensen, TIA ;
Andersen, T ;
Auwerx, J ;
Pedersen, O .
DIABETOLOGIA, 1999, 42 (07) :892-895